Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

In-silico identification of anti-cholera phytochemicals from Indian medicinal plants

  • Khalilur Rahman,

    Roles Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft

    Affiliations icddr, b, (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh, Bioinformatics Lab (dry), Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh

  • Yasmin Akter,

    Roles Writing – original draft

    Affiliation icddr, b, (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh

  • Md Selim Reza,

    Roles Methodology

    Affiliations Bioinformatics Lab (dry), Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh, Tulane Center for Biomedical Informatics and Genomics, Deming Department of Medicine, School of Medicine, Tulane University, New Orleans, Louisiana, United States of America

  • Md. Al Amin Pappu,

    Roles Investigation, Software

    Affiliation Bioinformatics Lab (dry), Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh

  • Md. Rezaul Karim,

    Roles Writing – review & editing

    Affiliation Department of Biotechnology & Genetic Engineering, Faculty of Biological Science, Islamic University, Kushtia, Bangladesh

  • Marzia Sultana,

    Roles Writing – review & editing

    Affiliation icddr, b, (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh

  • Mohammad Tarequl Islam,

    Roles Writing – review & editing

    Affiliation icddr, b, (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh

  • Munirul Alam,

    Roles Supervision, Writing – review & editing

    Affiliation icddr, b, (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh

  • Md Nurul Haque Mollah ,

    Roles Project administration, Supervision, Writing – review & editing

    mollah.stat.bio@ru.ac.bd (MNHM); mamun.monir@icddrb.org (MMM)

    Affiliation Bioinformatics Lab (dry), Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh

  • Md. Mamun Monir

    Roles Conceptualization, Supervision, Writing – review & editing

    mollah.stat.bio@ru.ac.bd (MNHM); mamun.monir@icddrb.org (MMM)

    Affiliation icddr, b, (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh

Abstract

Cholera is a severe diarrheal disease caused by ingestion of food or water contaminated with pathogenic Vibrio cholerae. Treatment for cholera includes rehydration therapy and antibiotics to avert death and reduce bacterial burden to prevent rapid transmission of the disease. In addition, in Indian subcontinent, there is historical evidence of using plants for treating cholera. This study was designed to investigate the cholera toxin-inhibitory properties of phytochemicals sourced from Indian medicinal plants. For this, three reported genotypes of cholera toxin subunit B (ctxB) associated with 7PET V. cholerae O1 El Tor strains were used as targets in molecular docking. Analysis results showed strong binding affinities (≤−7.5 kcal/mol) for 298 out of 7,607 phytochemicals, with minor variations for the ctxB genotype-specific targets. Multiple phytochemicals from the same plants were identified with high binding affinities, e.g., 101 from Morus alba, 24 from Citrus aurantium, 17 from Emblica officinalis, and 16 from Capsicum annuum. However, further analyses, including drug-likeness, pharmacokinetics, and toxicity, identified five promising phytochemical candidates, namely, Abyssinone V (Azadirachta indica), Diosgenin (Achyranthes bidentata), Yamogenin (Borassus flabellifer), and two other unnamed phytochemicals (one from Azadirachta indica and one from Morus alba) for cholera toxin inhibition. Molecular dynamics simulation using YASARA and GROMACS showed structural stability of the ctxB-phytochemical complexes, while exhibiting adaptive rearrangements of ligand within the active binding sites of the proteins. In the simulations, MM-PBSA binding free energies showed a favorable total binding energy for the complexes. Per-residue energy decomposition analysis identified different highly contributing sets of amino acids to the binding energy with variation for both ctxB genotypes and phytochemicals, suggesting bacterial evolutionary changes may affect binding patterns of the drug candidates. This study suggests five inhibitors of cholera toxin with varying genotypes, which may have potential as an alternative medication for cholera.

1. Introduction

Cholera remains a major global health challenge, caused by pathogenic Vibrio cholerae, particularly in regions with inadequate hygiene and sanitation [13]. It often leads to severe dehydration and is characterized by the profuse release of a significant volume of fluid resembling rice-water diarrhea [1,2]. Nearly 3 million cases of cholera are reported annually, with deaths ranging from 21,000–143,000, and a notable upsurge has been observed since 2021 [46]. Cholera was associated with the classical biotype of V. cholerae O1 until the sixth pandemic, which began in 1817, whereas the ongoing seventh cholera pandemic, starting in the early 1960s, has been linked to V. cholerae O1 El Tor biotype [1]. In 1992, V. cholerae O139 emerged in India and subsequently in Bangladesh, producing the same cholera enterotoxin [2,7]. The global rise in El Tor cholera cases may be due to enhanced ability to thrive in aquatic environmental reservoirs, reflected by upregulated gene expression involved in biofilm formation, chemotaxis, and nutrient transport, such as iron, peptides, and amino acids [8,9].

The most effective treatment of cholera is oral rehydration saline (ORS) [10]. However, it alone does not eliminate the pathogen or prevent the mode of cholera toxin [11]. Besides, a two-dose regimen of antibiotics, such as tetracycline, fluoroquinolone, erythromycin, and azithromycin, has been used for the treatment of cholera for a long period of time, aiming to decrease the pathogen burden and reduce disease transmission [12,13]. However, a concerning trend of resistance to antibiotics has been driven by irrational use of these antibiotics, along with other selective pressures [14]. Recent studies observed numerous antibiotic-resistant V. cholerae O1 strains carrying multiple antibiotic-resistance genes over the years [1517]. Therefore, researchers have been considering alternative therapeutic approaches to combat cholera, including vaccines, probiotics, peptides, bacteriophages, and phytochemicals [1823]. Vaccines have emerged as a promising alternative, but their availability remains limited compared to the high demand [5,2428]. While some other approaches are under investigation, medicinal plant-derived phytochemicals, in particular, hold significant promise as an alternative therapy [2932]. In the Indian subcontinent, it is a common practice to use various parts of medicinal plants (such as leaves, bark, roots, and fruits) to treat different diseases. A recent effort led to the development of a database called IMPPAT 2.0 (Indian Medicinal Plants, Phytochemistry And Therapeutics) [33], which stores information about Indian medicinal plants and their compounds for numerous therapeutic uses from traditional books, published articles, and other resources, including cholera.

Cholera toxin is the primary virulence factor of V. cholerae infection (cholera) and consists of two subunits, A and B [34]. During infection, the B subunit binds to the primary receptor, the monosialoganglioside GM1, located on the surface of host enterocytes, which allows internalization of the A subunit, which elevates intracellular cAMP levels, triggers the excessive secretion of water and electrolytes, leading to profuse diarrhea [3537]. Recent studies have revealed that cholera toxin subunit B also binds to fucosylated receptors, such as histo-blood group antigen, and may cause infection, even when GM1 synthesis is inhibited [3842]. Therefore, we investigated a therapeutic approach using phytochemicals to inhibit ctxB from binding to host receptors.

In this study, molecular docking, ADMET, and drug-likeness properties were analyzed to identify the potential plant-derived phytochemicals considering ctxB genotypes (ctxB1, ctxB3, and ctxB7) as targets. The stability of complexes between identified phytochemicals and ctxB was validated by molecular dynamics simulations using YASARA and GROMACS. Furthermore, average MM-PBSA binding free energy was calculated to assess binding favorability, and per-residue energy decomposition analysis was conducted to identify and quantify the energetic contribution of individual amino acids involved in ctxB-phytochemical complexes.

2. Materials and methods

2.1 Data source and description

Cholera toxin subunit B (ctxB) serves as a crucial biomarker for understanding the mechanism of V. cholerae infection [34]. The toxin gene initiates infection by binding to the specific host receptors [3542]. In this study, protein sequences of the ctxB were collected from NCBI for the 3D structure prediction and subsequently used for molecular docking analysis.

Different diseases have been treated by using the resources from medicinal plants in the Indian subcontinent [43,44]. The IMPPAT (Indian Medicinal Plants, Phytochemistry and Therapeutics) database listed 4,010 Indian medicinal plants based on the information from more than 100 herbal medicine books, published studies, and other resources [33]. The database provides comprehensive information about the plants traditionally suggested for 1,095 therapeutic uses, including cholera. This study utilized information from the database to identify a list of plants that were traditionally used or suggested for cholera treatment.

2.1.1 Target identification.

Thirteen genotypes of ctxB have been reported to date through experimental approaches such as conventional PCR, qPCR, and in-silico analysis, with ctxB1, ctxB3, and ctxB7 being linked to the ongoing seventh cholera pandemic [4557]. The V. cholerae O1 El Tor strains primarily contained the ctxB3 genotype before adopting the classical ctxB1 genotype [48,49]. In addition, the 2010 Haiti cholera outbreak was associated with another mutant variant of cholera toxin, namely ctxB7, which was first reported in Odisha, India, in 1999 [58]. According to recent studies, circulating strains in Asia, Africa, and other endemic regions mostly carry the ctxB7 genotype [4559]. In Bangladesh, strains with ctxB1 and ctxB7 genotypes co-existed up to 2019, after that, only strains with ctxB7 were reported [16,46,57,60,61]. Considering these changes over time, we used all three genotypes of ctxB as drug targets, with the additional aim to understand the possible changes in the drug candidates due to bacterial evolutionary changes often observed.

2.1.2 Collection of phytochemicals as drug agents.

IMPPAT 2.0 database listed a total of 177 medicinal plants as resource for traditional cholera treatment [33]. Among these, we considered 55 widely known medicinal plants, which are largely available locally in Bangladesh. We then searched these plants in the PubChem database [62] to retrieve all related phytochemicals along with the available 3D structures. Phytochemicals found in multiple plants were listed only once under a specific plant. A total of 7,607 unique phytochemicals from different plants were collected and analyzed in this study (S1 Dataset). This study was entirely based on secondary data. No human participants or animals were involved. Verbal permission to conduct this study was obtained from the research administration (RA) of our institute.

2.2 Preprocessing of drug targets and agents

The 3D structures of the ctxB genotype were predicted from protein sequences retrieved from NCBI using SWISS-MODEL [63]. Quality of the predicted protein structures was assessed by the Ramachandran plot [64], which was further protonated at 7.4 pH using PDB2PQR [65] and H++ [66]. From protein structures, water molecules, attached ligands, and heteroatoms were removed, and then Kollman charges, the required hydrogen atoms were added by using AutoDockTools [67]. Finally, the processed structures were stored in pdbqt format for molecular docking.

The 3D structures of phytochemicals were downloaded in SDF format from the PubChem database [62]. Energy minimization of the collected phytochemicals was conducted using OpenBabel [68], with the customized MMFF94 force field, applying the steepest descent algorithm with a maximum of 5,000 iterations, and the structures were saved in PDB format. Furthermore, Gasteiger charges were added, and the torsion tree, including both rotatable and non-rotatable bonds in the phytochemicals, was defined using AutoDockTools, and the file was stored in pdbqt format.

2.3 Screening of phytochemicals by molecular docking analysis

Grid box was generated to cover the whole protein surface with a default spacing value (0.375 Å) by using AutoDockTools [67], and then a config file was manually created for 3D coordinates and size of the box with exhaustiveness value equal to 8. For ctxB1, the grid box was centered at coordinates x = −6.433, y = 11.478, and z = 10.41, with a box size of 78 × 66 × 84 grid points along the x, y, and z axes, respectively. Similarly, for ctxB3, the center was positioned at x = −11.478, y = −15.787, and z = 15.47, with a grid box size of 80 × 58 × 76 grid points. And, for ctxB7, the grid box was centered at x = −7.05, y = 13.034, and z = 9.081, with 78 × 60 × 78 grid points. Molecular docking was performed using AutoDock Vina [69,70], which employs a scoring function based on steric complementarity, hydrophobic interaction, hydrogen bonding, and a penalty for ligand flexibility to estimate binding affinities of the phytochemical and target protein complexes, and uses a gradient-based conformational search to identify the most stable binding pose (lowest energy). Phytochemicals that met the defined threshold of binding affinity were shortlisted for further ADMET analysis.

2.4 ADME/T analysis

The ADME/T (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis of the top-ranked phytochemicals was conducted to facilitate the prediction of drug-like properties, pharmacokinetics, and pharmaceutical characteristics and toxicity of the phytochemicals by using four different online tools, such as SwissADME [71], pkCSM [72], admetSAR 3.0 [73], and ADMETlab 3.0 [74]. SwissADME, pkCSM, and admetSAR 3.0 were used to evaluate ADME parameters, while pkCSM, admetSAR 3.0, and ADMETlab 3.0 were used to assess the toxicity parameters. A consensus-based approach was applied, where the outcome of a parameter was accepted only if at least two tools agreed. Lipophilicity (XLOGP3), topological polarity surface area (TPSA), solubility (log S), rotatable bonds, and Lipinski’s Rule of Five (Molecular weight ≤ 500 daltons, MLOGP ≤ 4.15, hydrogen bond donors (HBD) ≤ 5, and hydrogen bond acceptors (HBA) ≤ 10) [75] were applied for investigating the physicochemical properties of the phytochemicals. Pharmacokinetics properties included Blood Brain Barrier (BBB) permeability, Human Intestinal absorption (HIA), P-glycoprotein (PGP), and five major isoforms from the cytochromes P450 (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) [76,77]. For toxicity analysis, AMES toxicity, hERG (human ether-a-go-go related gene) inhibition, human hepatotoxicity, and rat toxicity (LD50) were considered. Non-bonded interactions of the ctxB-phytochemical complexes, including their categories and types, were visualized using Discovery Studio Visualizer [78].

2.5 Molecular dynamics (MD) simulation

Molecular dynamics simulations were executed to evaluate the stability of ctxB-phytochemical complexes by using YASARA software [79]. The initial MD simulation run was executed for 100 ns using YASARA md_run.mcr script (https://www.yasara.org/md_run.mcr). In the script, the default AMBER14 (Assisted Model Building with Energy Refinement) force field [80] was utilized to determine the dynamic behavior of the ctxB-phytochemical complexes, and the TIP3P (Transferable Intermolecular Potential 3 Points) water model [81] was applied to optimize the hydrogen bonding network of the complexes. A water density of 0.997 g/ml was considered to maintain periodic boundary conditions. The simulation took place in a cubic virtual environment with default physiological conditions (pH of 7.4, the ion concentration of 0.9% NaCl, 298 K temperature, and constant pressure), and long-range Coulomb forces [82,83]. The initial energy of each complex was minimized using simulated annealing with the steepest gradient approach over 5,000 cycles. After minimization, a built-in macro script (https://www.yasara.org/md_run.mcr) of YASARA was used to equilibrate the system under controlled conditions to reach stable temperature, pressure, and density. Equilibration was performed under the NVT ensemble, where the temperature was gradually brought to the target (298K) using a Berendsen thermostat [84], and the solvent density was maintained at a constant level (thereby keeping the pressure effectively constant) using Densostat [82]. Simulation snapshots were stored every 250 ps (fast step) in sim format (.sim), and the trajectories were captured. The Root mean square deviation of protein backbone (RMSDBb), ligand movement RMSD, ligand conformation RMSD, radius of gyration (Rg), Root mean square fluctuations (RMSF), number of hydrogen bonds, per-residue protein secondary structure changes, per-residue contact with ligand, and protein secondary structure content were analyzed using the md_analyze.mcr script (https://www.yasara.org/md_analyze.mcr). The analyzed results were visualized by custom Python scripts. In addition, MD simulations for all of the complexes were also conducted using GROMACS and compared with the results from YASARA (S1 File).

2.6 Binding free energy and per-residue energy decomposition

Binding energies were calculated using MM-Poisson-Boltzmann surface area (MM-PBSA) with the AMBER14 force field [80] at 298K in a cuboid cell using YASARA (https://www.yasara.org/md_analyzebindenergy.mcr) [79,85,86]. The software has used the following formula to calculate binding energy:

Here, Epot denotes gas-phase molecular mechanics potential energy, including bonded, electrostatic, and van der Waals interactions, and Esolv denotes total solvation energy, consisting of both polar (Poisson-Boltzmann) and non-polar (Surface accessible surface area-based) contributions. EpotComplex and EsolvComplex refer to the potential energy and solvation energy of the total complex. EpotRecept and EsolRecept refer to the potential energy and solvation energy of the receptor. EpotLigand and EsolvLigand refer to the potential energy and solvation energy of the ligand.

Per-residue energy decomposition analysis was performed to quantify the energetic contribution of amino acids involved in ctxB-phytochemical complexes. For this, all complexes were subject to 100 ns MD simulations using GROMACS [87], and the resulting trajectories were analyzed (see S1 File). g_mmpbsa tool [88] was used for residue-level energy decomposition. This tool first decomposes the overall MM-PBSA binding energy of the protein-ligand complex, then calculates the contributions of each residue. MM-PBSA binding free energy was also calculated using the g_mmpbsa tool (see S1 File). Moreover, backbone RMSD (RMSDBb), ligand movement RMSD, ligand conformation RMSD, radius of gyration (Rg), RMSF, and hydrogen bond counts were obtained from both YASARA and GROMACS.

3. Results

3.1 Structure prediction of the ctxB mutants

Three genotypes of the ctxB gene (ctxB1, ctxB3, and ctxB7) have been observed in the 7th pandemic V. cholerae O1 El Tor strains, which are characterized by three-point mutations. All of the genotypes have a total of 124 amino acids (S2 Dataset). ctxB3 differs from ctxB1 by two amino acid substitutions: HIS39 replaced TYR39, and THR68 replaced ILE68, whereas ctxB7 has an extra single nucleotide change within the signal peptide region (1−21 amino acids), ASN20 replaced HIS20. The predicted 3D structures of the proteins encoded by three distinct ctxB genotypes were displayed in Fig 1A-C, and prediction details are provided in S1 Table. Signal peptide region (first 21 amino acids) of the target protein (ctxB genotypes) didn’t have an equivalent crystal structure. Most of the amino acid residues for the predicted structures were located within the high (under green polygon) and moderate (under light-green polygon) confidence regions of phi (φ) and psi (ψ) dihedral angles in the Ramachandran plot, indicating the structural validity of the predicted models (Fig 1D-F). TM-align was used to observe the differences between the predicted structures of three ctxB genotypes [89]. ctxB1 and ctxB7 were highly similar (RMSD-0, sequence identity-1.0), while both showed slight differences from ctxB3 (RMSD-0.26, sequence identity-0.981).

thumbnail
Fig 1. Predicted structures and Ramachandran plots for ctxB genotypes.

Panels (A-C) show the predicted 3D structures of ctxB3 (A), ctxB1 (B), and ctxB7 (C) using SWISS-MODEL. Mutant positions were highlighted in yellow, and corresponding amino acids were highlighted in the plots. Quality of the predicted structures was evaluated using Ramachandran plots (D-F). In the plots, confidence regions were visualized using three different green color intensities for referring to highly favored (green color shade), allowed (light green color shade), and generously allowed (extra-light green color shade) backbone φ and Ψ dihedral angles of each amino acid residue in protein structures. Most of the amino acid residues within the high (under green polygon) and moderate (under light-green polygon) confidence regions indicate the reliability and structural validity of the predicted models.

https://doi.org/10.1371/journal.pone.0342058.g001

3.2 Screening of phytochemicals by molecular docking analysis

Molecular docking was employed to calculate the binding affinity scores (kcal/mol) of the selected 7,607 phytochemicals against proteins encoded by three genotypes of ctxB (ctxB1, ctxB3, and ctxB7). A binding affinity of less than −7 kcal/mol is generally considered indicative of strong affinity binding [90]. In this study, we used a slightly higher cutoff for binding affinity (≤ −7.5 kcal/mol) to identify high-confidence interactions. A total of 298 phytochemicals were shortlisted based on the binding affinity cutoff, of which 101 were from Morus alba, 24 from Citrus aurantium, 17 from Emblica officinalis, 16 from Capsicum annuum, 15 from Psidium guajava, and 125 phytochemicals from 32 other plants (S3 Dataset and S2 Table).

3.3 ADME/T analysis

ADME/T analysis was performed to investigate the pharmacokinetic properties of the selected phytochemicals with docking score ≤ −7.5 kcal/mol. Out of 298 phytochemicals, 87 satisfied physicochemical properties, such as lipophilicity (ref. range: −0.7 < XLOGP3 < +6.0), topological polarity surface area (ref. range: 20Ų < TPSA < 140Ų), solubility (ref. range: log S not higher than 6), and rotatable bonds (ref. ≤ 9). In addition, optimum physicochemical properties were observed for another 16 phytochemicals with only little higher lipophilicity (obs. range: + 6.0 < XLOGP3 < +6.8) (S4 Dataset). Among the total 103 (n = 87 + 16) phytochemicals with optimum physicochemical properties, 41 satisfied several additional pharmacokinetic properties, including Blood Brain Barrier (BBB), Human Intestinal Absorption (HIA), P-glycoprotein (PGP), and the activity of five major isoforms (CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4) (Fig 2). Phytochemicals with satisfactory ADME properties can be extracted from M. alba (n = 11), M. paniculata (n = 4), C. maxima (n = 3), and several other plants (n = 2 × 6 + 1 × 11 = 23) (S2 Table). Note that the multiple candidate phytochemicals from the same plant source were recoded as Mol 1, Mol 2, etc., with a prefix of the respective plant name to further include them in the downstream analyses (S3 Table).

thumbnail
Fig 2. ADME/T analysis results of the 41 candidate phytochemicals.

Horizontal axis shows the re-coded name of the phytochemicals (with source plant name), and different color is used for highlighting source plants. Vertical axis shows different measurements for the ADME and toxicity properties. Dark blue color in the plot indicates presence, and light yellow indicates absence in a specific test result. Seven phytochemicals that satisfied for ADME/T criteria were considered in the subsequent analyses.

https://doi.org/10.1371/journal.pone.0342058.g002

After evaluating the ADME properties, toxicity properties were tested based on four different parameters, such as hERG inhibition, AMES toxicity, hepatotoxicity, and rat toxicity. Among 41 phytochemicals, 14 showed AMES positivity, hepatotoxicity, and rat toxicity, 3 showed AMES and hepatotoxicity, 2 showed hepatotoxicity and rat toxicity, and 15 others showed toxicities in at least one of four parameters. Remaining seven phytochemicals of the plants, M. alba (Mol 10), A. indica (Mol 1 and Mol 2), A. bidentata (Mol 1), B. flabellifer (Mol 2), C. annuum (Mol 1), and C. asiatica (Mol 1), passed in toxicity analysis.

3.4 Binding sites comparisons between the ctxB-host receptor and the ctxB-phytochemical complexes

Since cholera disease starts with the binding of ctxB to host receptors, observing the binding positions may provide valuable insights into the probable inhibitory properties. Cholera toxin can be inhibited at two different stages: (1) before being secreted, proper folding of the ctxB pentamer in the bacterial cytoplasm or periplasm can be prevented during the intracellular assembly [91], and (2) host cell binding stage: the secreted ctxB pentamer can be prevented from binding to the host receptors [38,39]. We searched for published literature to investigate the binding positions of the ctxB pentamer with two different receptors (GM1 and histo-blood group antigen Lewisx (Lex)). The primary receptor GM1 pentasaccharides mainly bind with ctxB (classical, similar to ctxB1) at GLU32, TYR33, HIS34, GLU72, HIS78, ILE79, GLN82, TRP109, ASN111, and LYS112 residues [92]. Binding positions of the ctxB and histo-blood group antigen Lewisx (Lex) complex, and the ctxB pentamer itself, were tabulated to identify active amino acid residues [9395] (S4 Table). Binding behaviors of ctxB and the 7 candidate phytochemicals (docking score ≤ −7.5 kcal/mol and passed in ADME/T analysis) were further investigated to understand their potential inhibiting properties. All the possible (3 × 7 = 21) complexes of potential ligands with three ctxB genotypes were analyzed, and it was observed that most of the phytochemicals (n = 6) interacted with several common amino acid residues (≥ 6) at which host receptors interact (S5 Dataset). Interestingly, a phytochemical from A. indica constructed bonds with ctxB at 11 amino acid residues, all of which are common to the binding residues of the ctxB-GM1 complex (Fig 3A-C). Similarly, a phytochemical from M. alba and ctxB complexes (three complexes for three different genotypes) produced 7–8 common amino acid residues to the ctxB pentamer interacting binding residues.

thumbnail
Fig 3. 3D and 2D visualizations of the ctxB-A. indica (Mol 1) complexes.

Here, 3D and 2D views of the complexes were visualized on the left and right sides of each figure, respectively. In the 3D view, orange-colored structures represent amino acids of ctxB, greenish-blue-colored structures represent phytochemicals, and dashed lines indicate hydrogen and hydrophobic bonds. In the 2D view, two different types of green circles (dark and extra-light) represent amino acids involved in hydrogen bonds, such as, dark green circle refers to conventional hydrogen bonds, and extra-light green circle refers to carbon-hydrogen bonds. Textualized forms of amino acid and positions highlighted by light green color represent van der Waals forces. Pink circle represents amino acids involved in hydrophobic bonds, and its different color intensity refers to hydrophobic bond types, such as dark pink refers to pi-pi stacked and pi-pi T-shaped bond, and light pink refers to pi-alkyl bond. A phytochemical of A. indica (Mol 1) interacted with ctxB genotypes through 11–12 amino acid residues, all of which are common for the ctxB-GM1 complex.

https://doi.org/10.1371/journal.pone.0342058.g003

3.5 Intermolecular interactions of ctxB and phytochemical complexes

We further investigated types of chemical interactions in the ctxB-phytochemical complexes. Analysis showed two hydrogen bonds, six hydrophobic bonds, and seven van der Waals forces in ctxB1-A. indica (Mol 1) complex. Two hydrogen bonds (conventional) were at the LYS112, GLU72, the six hydrophobic bonds were at TRP109 (two pi-pi stacked), TYR33 (pi-pi T-shaped), TYR33 (two pi-alkyl), HIS34 (pi-alkyl), and seven van der Waals forces at GLU32, ASN35, GLN77, HIS78, ILE79, GLN82, and ASN111 (Fig 3A). ctxB7-A. indica (Mol 1) complex showed identical interactions as ctxB1-A. indica (Mol 1) complex (Fig 3B). Slight variations in binding types and positions were observed for ctxB3-A. indica (Mol 1) complex (Fig 3C). Similarly, chemical interactions and binding types of the other four candidate phytochemicals were listed in Table 1, and the 2D views of these complexes were visualized in S1 Fig.

thumbnail
Table 1. The non-bonded interaction of phytochemicals and ctxB genotypes.

https://doi.org/10.1371/journal.pone.0342058.t001

3.6 Molecular dynamics simulations

Molecular dynamics simulations were conducted using YASARA for 100 ns to observe variations in protein backbone RMSD, ligand movement RMSD, ligand conformation RMSD, radius of gyration, protein residue root mean square fluctuation (RMSF), number of hydrogen bonds, per-residue protein secondary structure changes, per-residue contact with ligand, and overall protein secondary structure contents for different complexes. In simulation, minor variations were observed for each of the phytochemicals and two different targets (ctxB3 and ctxB7 genotypes). For example, analysis results for A. indica (Mol 1) were very similar for the complexes with ctxB3 and ctxB7. Protein backbone RMSD and radius of gyration were quite stable after initial equilibration for both ctxB3-A. indica (Mol 1), and ctxB7-A. indica (Mol 1) complexes, reflecting the stability of overall protein folding and its compactness throughout the 100 ns simulation (Fig 4A, D). In ctxB3, ligand movement RMSD remained relatively low (~6 Å), and conformational RMSD around ~3 Å, suggesting that the ligand remained largely within the initial binding pocket while adapting its internal conformation (Fig 4B, C). In contrast, the ligand bound to ctxB7 exhibited an increase in movement RMSD from ~5 Å during the initial 45 ns to ~11 Å thereafter, conformational RMSD also increased from ~3 Å to ~4 Å after 45 ns, indicating that the ligand may have explored different binding pockets to exhibit more structural flexibility of the ligand (Fig 4B, C). A. indica (Mol 1) interact with ctxB through mostly hydrophobic bonds (S6E, F Fig), whereas, only a hydrogen bond was observed in almost all of the time points for ctxB3-A. indica (Mol 1) complex, but was rare for the ctxB7-A. indica (Mol 1) (Fig 4F, G). For these complexes, β-sheet content (~38–42%) and α-helix content (~24–28%) were stable at overall and residue levels, whereas turn and coil regions fluctuated moderately throughout the simulation (S6A-D Fig). The higher RMSF values were mainly observed in two regions, residues 50–57 and 76–78 (Fig 4E). Similarly, all other phytochemical-ctxB complexes showed comparable behavior throughout the simulation (S6-S10 Fig). Interestingly, ligand movement RMSD was generally higher for all complexes, although B. flabellifer (Mol 2), A. bidentata (Mol 1), and A. indica (Mol 2) did not exhibit significant conformational changes and remained stable in their initial structural forms (S2, S4-S5 Fig). Simulation analysis using GROMACS yielded similar results for the complexes (S11-S15 Fig).

thumbnail
Fig 4. Molecular dynamics simulation results for ctxB3-A. indica (Mol 1) and ctxB7-A. indica (Mol 1) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-A. indica (Mol 1) complex, and (G) number of hydrogen bonds in ctxB7-A. indica (Mol 1) complex. In each of the plots, the horizontal axis represents simulation time (in ns), and the vertical axis represents the measured values of different analyses, except for (E), where the horizontal axis represents the residue index. The green line indicates ctxB3-A. indica (Mol 1) complex, and the blue line indicates ctxB7-A. indica (Mol 1) complex. The protein backbone RMSD and radius of gyration are stable, and RMSF fluctuates in the coil/turn regions. Ligand movement RMSD increased gradually for ctxB7-A. indica (Mol 1) complex, indicated positional rearrangement within the binding site, while the ligand conformation RMSD reflected substantial internal structural adjustments.

https://doi.org/10.1371/journal.pone.0342058.g004

3.7 MM-PBSA binding free energy

The MM-PBSA method was employed to estimate the binding free energies of all ctxB-phytochemical complexes using two software packages, YASARA and GROMACS. The calculated average binding energies of each complex with individual energy components are shown in Table 2. The average binding energies calculated using YASARA were favorably higher (positive scale for favorable binding), ranging between 93.58 and 152.06 kJ/mol, except for ctxB7-M. alba (mol 10) complex (average binding energy = 7.17 kJ/mol). The binding energies of this complex were relatively low during the initial 25 ns, increased between 25 and 50 ns, again decreased between 50 and 70 ns, and subsequently stabilized at higher values, with an average binding energy of 66.191 kJ/mol between 70 ns and 100 ns (S16 Fig). On the other hand, GROMACS results showed that two phytochemicals from A. indica exhibited comparatively more favorable binding energies (negative scale for favorable binding) to both ctxB variants, whereas M. alba (mol 10) showed the least favorable energies. Most of the complexes displayed large negative VdW energies (−70.868 to −132.813 kJ/mol), indicating hydrophobic interactions were the main stabilizers. Nonpolar solvation energy (SASA) was also favorable for the complexes (−9.887 to −17.305 kJ/mol). The ctxB7-A. indica (mol 1) complex showed a strong electrostatic energy contribution (−47.633 kJ/mol), whereas it was relatively smaller in other complexes. Polar solvation energies were positive (38.071 to 99.500 kJ/mol), reducing net binding. However, both YASARA and GROMACS showed favorable average binding energies for all of the complexes (S16 Fig).

thumbnail
Table 2. The MM-PBSA binding free energy by YASARA and GROMACS.

https://doi.org/10.1371/journal.pone.0342058.t002

3.8 Per-residue binding energy decomposition

Per-residue binding energy decomposition was performed to evaluate the contributions of individual amino acid residues of ctxB in binding. It was observed that mostly different sets of high contributing residues for ctxB3 and ctxB7, when its interact with the same phytochemical. For example, binding of A. indica (mol 1) with ctxB3, ILE60 (−11.214kJ/mol), ILE68 (−4.357 kJ/mol), THR49 (−4.281 kJ/mol), PRO114 (−4.277 kJ/mol), MET58 (−3.377 kJ/mol), THR62 (−2.318 kJ/mol), and GLU50 (−2.283 kJ/mol) were the top contributors, whereas, TRP109 (−4.739 kJ/mol), MET89 (−3.563 kJ/mol), TYR33 (−2.425 kJ/mol), ILE86 (−2.346 kJ/mol), and LEU29 (−2.176 kJ/mol) were the top contributors when the phytochemical binds with ctxB7. We obsevered exceptions only for M. alba (Mol 10) and A. bidentata (Mol 1), whereas similar set of residues of ctxB3 and ctxB7 contributed largely (Fig 5A-B, S17 Fig). All residues contributing moderately (≤−0.2 kJ/mol) to strongly (≤−11.214 kJ/mol) to the binding energy for all of the complexes were tabulated in S6 Dataset. Amino acid residues collectively account for ~80% of the total binding energy, and individual contribution ≤ −0.5 kJ/mol were listed and visualized (S18 Fig). A total of 70 out of 124 amino acid residues were found as high contributors for the different complexes.

thumbnail
Fig 5. Per residue binding free energy decomposition of ctxB-phytochemical complexes.

Panel A shows Morus alba (Mol 10), Panel B shows Achyranthes bidentata (Mol 1), and Panel C shows Borassus flabellifer (Mol 2). In each of the panels, the horizontal axis represents ctxB variants (ctxB3, ctxB7), and the vertical axis represents the positions of the amino acid residues. Orange color indicates negative (favorable) values, purple indicates positive (unfavorable) values, and white denotes near-zero contributions. For both ctxB3 and ctxB7, M. alba (Mol 10) and A. bidentata (Mol 1) shared a comparable profile of major amino acid contributors to the total binding energy.

https://doi.org/10.1371/journal.pone.0342058.g005

3.9 Intermolecular interactions after simulation

Binding residues of the complexes were reobserved after simulation. The total non-bonded interactions and interacting residues increased in almost all complexes except for the ctxB7-M. alba (Mol 10) (interacting residues decreased from 13 to 8), and ctxB7-A. bidentata (Mol 1) (interacting residues decreased from 9 to 8) complexes. Each complex changed some of its interacting residues after simulation. A detailed list of all the non-bonded interactions before and after the simulation was provided in S7 Dataset. It was noted that the complexes showed an increasing number of common residues with the pentamer-interacting residues after simulation. However, exceptions were for Mol 1 and Mol 2 of A. indica, and for these interacting residues of ctxB-phytochemical were mostly common to the interacting residues of ctxB-GM1 complex.

4. Discussion

Antimicrobial resistance is often referred to as a silent pandemic, which would be responsible for taking millions of lives in the near future [96,97]. Increasing trend of multidrug resistance to the existing antibiotics represents a growing challenge for future treatment strategies, highlighting the need for alternative therapeutic approaches. Medicinal plants/herbs have been utilized as a source of many traditional medicines since ancient times, and still serve as a primary source of novel drugs in the pharmaceutical industry [98]. With the advantages of recent technological advancements, the identification and validation of natural products may aid in their effective use and repurposing for treating different diseases. This study conducted in-silico identification and validation of plant-derived phytochemicals for treating cholera disease by targeting cholera toxin with the goal of complementing current cholera treatment strategies. Pathogenic V. cholerae strains carry CTX prophage gene cassette, including cholera toxin-encoding genes [99,100]. The mechanism of cholera toxin (ctxAB) initiates with the high-affinity attachment of its B subunits to host monosialoganglioside GM1 receptors or through comparatively low-affinity binding to secondary receptors [3442]. Thus, inhibiting this initial interaction of the toxin could prevent the pathogenicity of V. cholerae infection and the onset of cholera [101107]. With genomic evolutionary progression of the 7PET V. cholerae O1 El Tor strains over time, three genotypes of ctxB (ctxB1, ctxB3, and ctxB7) were observed. A previous study showed the variations in the binding ability of different genotypes of ctxB to GM1 [108]. Therefore, in this study, proteins encoded by three different genotypes of ctxB were considered as targets. The resource of IMPPAT database served as primary base for including a list of 7,607 phytochemicals incorporating historical information of the corresponding 55 source plants used for treating cholera. After subsequent molecular docking analysis of the phytochemicals, 298 potential compounds were identified based on high binding affinity (≤ −7.5 kcal/mol), which can be sourced from 37 medicinal plants, including Morus alba, Citrus aurantium, Emblica officinalis, Capsicum annuum, and Psidium guajava. Further drug-likeness and pharmacokinetics analysis reduced candidates to 41 phytochemicals, of which seven phytochemicals satisfied toxicity properties. Among these, six phytochemicals interacted with known active residues of ctxB, and one of which, from Capsicum annuum, has previously been reported to have toxic effects [109,110]. The remaining five phytochemicals, such as A. indica (Mol 1), A. bidentata (Mol 1), B. flabellifer (Mol 2), M. alba (Mol 10), and A. indica (Mol 2), were further analyzed for understanding their binding stability with ctxB. Molecular dynamics simulations over 100 ns showed stability in backbone RMSD and radius of gyration, which indicate global structural stability and compactness of protein-ligand complexes. Secondary structure analyses further confirmed the maintenance of α-helix and β-sheet elements throughout the simulation. In contrast, analyses of ligand movement RMSD and ligand conformational RMSD clearly showed that all of the phytochemicals shifted from their initial binding pockets, with some exhibiting internal conformational changes. These trends were also consistently observed in GROMACS analysis results. Additionally, minor secondary structure transitions occurred in flexible turn and coil regions, suggesting that these regions accommodate ligand-induced conformational adjustments. The higher RMSF values were also observed for all complexes in the coil and turn regions, reflecting their inherent flexibility and potential role in ligand binding. The total number of hydrogen bonds and per-residue ligand contact analyses revealed that hydrophobic interactions were the main driving force for the binding of the complexes. Most of the complexes exhibited favorable MM-PBSA binding free energies in both YASARA and GROMACS simulations. GROMACS results indicated that M. alba (mol 10) had the least favorable binding (less negative) with ctxB genotypes among the five phytochemicals. The large contribution of van der Waals energies to total binding energy for all complexes further highlighted the importance of hydrophobic interactions in complex stabilization. Per-residue energy decomposition revealed that different complexes were stabilized by distinct sets of amino acids, collectively reflecting a diverse pattern of interactions. Intermolecular interactions after YASARA simulations showed that all phytochemicals altered their initial interacting residues, whereas A. indica (Mol 1), A. indica (Mol 2) maintained significant interactions with GM1-binding residues.

Although phytochemicals were listed in this study based on specific plants, a phytochemical can be found in several plants. For example, a phytochemical named A. indica (Mol 1) in this study, originally known as Abyssinone V, a prenylated flavonoid, can be found in several plants, such as Erythrina abyssinica, Azadirachta indica (neem). In addition, the candidate phytochemicals identified in this study have also been reported in previous studies for treating other diseases. For example, Abyssinone V (named in this study as A. indica (Mol 1)) has been reported as an inhibitor of the varicella-zoster virus [111]. Another phytochemical named A. bidentata (Mol 1), originally known as Diosgenin, a steroidal sapogenin, has been shown as beneficial for cognitive function and useful for treating several diseases [112]. B. flabellifer (palm) (Mol 2), originally known as Yamogenin, is a diastereomer of diosgenin, reported as an inhibitor of lipid accumulation in hepatocytes [113]. The other two phytochemicals, M. alba (Mol 10) and A. indica (Mol 2), have not been reported yet.

5. Conclusion

This study explored the potential phytochemicals that can be extracted from the medicinal plants historically used for treating cholera in the Indian subcontinent, providing theoretical relevance of using those plants and alternative medications for treating the disease. We investigated the binding behaviors of the phytochemicals with ctxB and identified toxin-inhibitory properties for a large set of phytochemicals. However, many compounds were identified as toxic, and only five from 7,607 phytochemicals were found to be as most promising candidates for inhibiting cholera toxin. Now, further in vitro and in vivo experimental studies are required to evaluate the effectiveness of the candidate phytochemicals.

Supporting information

S1 File. Supplementary methods for GROMACS simulations.

Detailed descriptions of system preparation, simulation parameters, equilibration, production runs, and trajectory analyses (e.g., RMSD, RMSF, Radius of gyration, number of hydrogen bonds, MM-PBSA binding energy) were performed using GROMACS.

https://doi.org/10.1371/journal.pone.0342058.s001

(DOCX)

S1 Table. Structural prediction details of ctxB toxin alleles using SWISS-MODEL.

Model quality metrics (QSQE, GMQE), and template information for ctxB alleles are provided.

https://doi.org/10.1371/journal.pone.0342058.s002

(DOCX)

S2 Table. Plant-specific phytochemicals at different screening steps.

Distribution of phytochemicals from individual plant sources across successive screening steps, including molecular docking, drug-likeness, and pharmacokinetic filtering.

https://doi.org/10.1371/journal.pone.0342058.s003

(DOCX)

S3 Table. Phytochemicals with recoded names.

Original phytochemical names, their PubChem ID, and corresponding recoded names are listed.

https://doi.org/10.1371/journal.pone.0342058.s004

(DOCX)

S4 Table. The active residues of ctxB.

Key amino acid residues involved in ligand binding and toxin functionality are reported.

https://doi.org/10.1371/journal.pone.0342058.s005

(DOCX)

S1 Dataset. Total phytochemicals used in the study.

A total of 7,607 phytochemicals extracted from 54 medicinal plants are listed, with their PubChem ID or source publications and corresponding source plant.

https://doi.org/10.1371/journal.pone.0342058.s006

(XLSX)

S2 Dataset. Protein sequence of ctxB genotype.

Protein sequences and sequence IDs of three ctxB genotypes (ctxB1, ctxB3, and ctxB7) are provided. All of the genotypes comprise 124 amino acids. Compared with ctxB1, ctxB3 contains two amino acid substitutions (HIS39 ◊ TYR39, and THR68 ◊ ILE68, whereas ctxB7 differs by a single nucleotide change within the signal peptide region (residues 1–21), resulting in an ASN20 ◊ HIS20 substitution.

https://doi.org/10.1371/journal.pone.0342058.s007

(TXT)

S3 Dataset. Phytochemicals exhibiting strong binding affinities in molecular docking.

A list of 298 phytochemicals showing binding affinity scores ≤ −7.5 kcal/mol in molecular docking is provided. PubChem IDs of listed phytochemicals and corresponding source plants are also included.

https://doi.org/10.1371/journal.pone.0342058.s008

(XLSX)

S4 Dataset. Phytochemicals with optimum physicochemical and drug-likeness properties.

Physiochemical and drug-likeness parameters, molecular weight, heavy atoms, aromatic heavy atoms, fraction Csp3, rotatable bonds, H-bond acceptors, H-bond donors, molar refractivity, TPSA, XLOGP3, WLOGP, consensus log P, ESOL log S, log Kp (cm/s), with the Lipinski rule are reported for corresponding phytochemicals.

https://doi.org/10.1371/journal.pone.0342058.s009

(XLSX)

S5 Dataset. Non-bonded interaction of phytochemicals satisfying ADMET properties.

Non-bonded interactions, including hydrogen bond (conventional, hydrogen-carbon, pi-donor), hydrophobic bond (alkyl, pi-alkyl, pi-pi stacked, pi-sulfur, pi-cation, pi-sigma), and van der Waals interaction were analyzed. Moreover, the common interactive residue and interaction number with GM1 or with pentamer formation sites were reported. ctxB1 and ctxB7 exhibited similar interaction patterns, and ctxB3 showed slight distinct interaction profiles.

https://doi.org/10.1371/journal.pone.0342058.s010

(XLSX)

S6 Dataset. Per-residue energy decomposition of ctxB-phytochemical complexes.

Per-residue contributions to the binding energy for all complexes are presented. Residues contribute moderately (≤−0.2 kJ/mol) to favorably (≤−0.5 kJ/mol), and their individual energy components (VdW-van der Waals force, Elec-electrostatic energy contribution, Pol-polar solvation energy, and SASA-nonpolar solvation energy) are presented. A diverse set of amino acid residues was identified as major contributors to binding.

https://doi.org/10.1371/journal.pone.0342058.s011

(XLSX)

S7 Dataset. Comparison of non-bonded interactions of before and after simulations.

Non-bonded interaction (hydrogen, hydrophobic, van der Waals, and others) of complexes between ctxB genotypes (ctxB3, ctxB7) and five selected phytochemicals are compared before and after molecular dynamic simulations, highlighting changes in interacting residues.

https://doi.org/10.1371/journal.pone.0342058.s012

(XLSX)

S1 Fig. 2D visualizations of the other four candidate phytochemicals complexed with ctxB.

Here, two different types of green circles (dark and extra-light) represent amino acids involved in hydrogen bonds, such as, dark green circle refers to conventional hydrogen bonds, and the extra-light green circle refers to carbon-hydrogen and pi-donor bonds. Textualized forms of amino acid and positions highlighted by light green color represent van der Waals forces. Pink circle represents amino acids involved in hydrophobic bonds, and its different color intensity refers to hydrophobic bond types, such as dark pink refers to pi-pi stacked and pi-pi T-shaped bond, and light pink refers to alkyl and pi-alkyl bond. In addition, the yellowish-brown color circle represents the electrostatic (pi-anion) and other (pi-sulfur) bonds. All complexes with ctxB1 showed identical interactions as the complexes with ctxB7. Slight variations in binding types and positions were observed for complexes with ctxB3.

https://doi.org/10.1371/journal.pone.0342058.s013

(TIF)

S2 Fig. Molecular dynamics simulation results by YASARA for ctxB3-A. indica (Mol 2) and ctxB7-A. indica (Mol 2) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-A. indica (Mol 2) complex, and (G) number of hydrogen bonds in ctxB7-A. indica (Mol 2) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents the measured values of different analyses, except for (E), where horizontal axis represents residue index. The green line indicates ctxB3-A. indica (Mol 2) complex, and the blue line indicates ctxB7-A. indica (Mol 2) complex. Ligand movement RMSD for ctxB7-A. indica (Mol 2) complex fluctuated mainly at 25 ns, suggesting that the ligand may have explored binding pockets other than the initial site. In contrast, the ligand remained in the pocket for ctxB3-A. indica (Mol 2) complex.

https://doi.org/10.1371/journal.pone.0342058.s014

(TIF)

S3 Fig. Molecular dynamics simulation results by YASARA for ctxB3-M. alba (Mol 10) and ctxB7-M. alba (Mol 10) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-M. alba (Mol 10) complex, and (G) number of hydrogen bonds in ctxB7-M. alba (Mol 10) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents the measured values of different analyses, except for (E), where horizontal axis represents residue index. The green line indicates ctxB3-M. alba (Mol 10) complex, and the blue line indicates ctxB7-M. alba (Mol 10) complex. Ligand movement RMSD for ctxB3-M. alba (Mol 10) complex shifted at the beginning of the simulation, and after which it remained stable. In contrast, ligand movement RMSD for ctxB7-M. alba (Mol 10) complex fluctuated notably around 25 ns, 45 ns, 70 ns, suggesting that the ligand may have explored several binding pockets beyond the initial site, with the changes in ligand conformation.

https://doi.org/10.1371/journal.pone.0342058.s015

(TIF)

S4 Fig. Molecular dynamics simulation results by YASARA for ctxB3-A. bidentata (Mol 1) and ctxB7-A. bidentata (Mol 1) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-M. bidentata (Mol 1) complex, and (G) number of hydrogen bonds in ctxB7-M. bidentata (Mol 1) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents measured values of different analyses, except for (E), where the horizontal axis represents residue index. The green line indicates ctxB3-M. bidentata (Mol 1) complex, and the blue line indicates ctxB7-M. bidentata (Mol 1) complex. Ligand movement RMSD for ctxB3-M. bidentata (Mol 1) complex shifted at the beginning of the simulation, and after which it remained stable. Whereas, ligand movement RMSD for ctxB7-M. bidentata (Mol 1) complex fluctuated shortly after simulation started and around 10 ns, suggesting that the ligand may have explored multiple binding pockets beyond the initial site.

https://doi.org/10.1371/journal.pone.0342058.s016

(TIF)

S5 Fig. Molecular dynamics simulation results by YASARA for ctxB3-B. flabellifer (Mol 2) and ctxB7-B. flabellifer (Mol 2) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-B. flabellifer (Mol 2) complex, and (G) number of hydrogen bonds in ctxB7-B. flabellifer (Mol 2) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents measured values of different analyses, except for (E), where horizontal axis represents residue index. The green line indicates ctxB3-B. flabellifer (Mol 2) complex, and the blue line indicates ctxB7-B. flabellifer (Mol 2) complex. Ligand movement RMSD for ctxB3-B. flabellifer (Mol 2) complex gradually increased until 60 ns, and after which it remained stable. Ligand movement RMSD for ctxB7-B. flabellifer (Mol 2) complex increased gradually until 65 ns, followed by a drift, suggesting that the ligand may have shifted from the initial binding pocket thereafter.

https://doi.org/10.1371/journal.pone.0342058.s017

(TIF)

S6 Fig. Secondary structure analysis of complexes of A. indica (Mol 1) with ctxB3 (left) and ctxB7 (right) over the entire 100 ns simulation time, analyzed using YASARA.

A and B show overall protein secondary structure content (%), and C and D represent per-residue secondary structure throughout the simulation, illustrating residue-level structural stability and transitions over time. Blue indicates α-helix, red indicates β-sheet, green indicates coil, cyan indicates turn, yellow indicates 310-helix, and orange indicates π-helix. E and F show per-residue ligand contact profiles with ctxB3 and ctxB7, respectively. Here, red indicates hydrogen bonds, green indicates hydrophobic bonds, and blue indicates ionic interactions. Also, mixtures of these three colors can show up if a certain residue is involved in more than one type of contact with the ligand. Overall, the dominant secondary structural elements remain stable throughout the simulation for both complexes.

https://doi.org/10.1371/journal.pone.0342058.s018

(TIF)

S7 Fig. Secondary structure analysis of complexes of A. indica (Mol 2) with ctxB3 (left) and ctxB7 (right) over the entire 100 ns simulation time, analyzed using YASARA.

A and B show overall protein secondary structure content (%), and C and D represent per-residue secondary structure throughout the simulation, illustrating residue-level structural stability and transitions over time. Blue indicates α-helix, red indicates β-sheet, green indicates coil, cyan indicates turn, yellow indicates 310-helix, and orange indicates π-helix. E and F show per-residue ligand contact profiles with ctxB3 and ctxB7, respectively. Here, red indicates hydrogen bonds, green indicates hydrophobic bonds, and blue indicates ionic interactions. Also, mixtures of these three colors can show up if a certain residue is involved in more than one type of contact with the ligand. Overall, the dominant secondary structural elements remain stable throughout the simulation for both complexes.

https://doi.org/10.1371/journal.pone.0342058.s019

(TIF)

S8 Fig. Secondary structure analysis of complexes of M. alba (Mol 10) with ctxB3 (left) and ctxB7 (right) over the entire 100 ns simulation time, analyzed using YASARA.

A and B show overall protein secondary structure content (%), and C and D represent per-residue secondary structure throughout the simulation, illustrating residue-level structural stability and transitions over time. Blue indicates α-helix, red indicates β-sheet, green indicates coil, cyan indicates turn, yellow indicates 310-helix, and orange indicates π-helix. E and F show per-residue ligand contact profiles with ctxB3 and ctxB7, respectively. Here, red indicates hydrogen bonds, green indicates hydrophobic bonds, and blue indicates ionic interactions. Also, mixtures of these three colors can show up if a certain residue is involved in more than one type of contact with the ligand. Overall, the dominant secondary structural elements remain stable throughout the simulation for both complexes.

https://doi.org/10.1371/journal.pone.0342058.s020

(TIF)

S9 Fig. Secondary structure analysis of complexes of A. bidentata (Mol 1) with ctxB3 (left) and ctxB7 (right) over the entire 100 ns simulation time, analyzed using YASARA.

A and B show overall protein secondary structure content (%), and C and D represent per-residue secondary structure throughout the simulation, illustrating residue-level structural stability and transitions over time. Blue indicates α-helix, red indicates β-sheet, green indicates coil, cyan indicates turn, yellow indicates 310-helix, and orange indicates π-helix. E and F show per-residue ligand contact profiles with ctxB3 and ctxB7, respectively. Here, red indicates hydrogen bonds, green indicates hydrophobic bonds, and blue indicates ionic interactions. Also, mixtures of these three colors can show up if a certain residue is involved in more than one type of contact with the ligand. Overall, the dominant secondary structural elements remain stable throughout the simulation for both complexes.

https://doi.org/10.1371/journal.pone.0342058.s021

(TIF)

S10 Fig. Secondary structure analysis of complexes of B. flabellifer (Mol 2) with ctxB3 (left) and ctxB7 (right) over the entire 100 ns simulation time, analyzed using YASARA.

A and B show overall protein secondary structure content (%), and C and D represent per-residue secondary structure throughout the simulation, illustrating residue-level structural stability and transitions over time. Blue indicates α-helix, red indicates β-sheet, green indicates coil, cyan indicates turn, yellow indicates 310-helix, and orange indicates π-helix. E and F show per-residue ligand contact profiles with ctxB3 and ctxB7, respectively. Here, red indicates hydrogen bonds, green indicates hydrophobic bonds, and blue indicates ionic interactions. Also, mixtures of these three colors can show up if a certain residue is involved in more than one type of contact with the ligand. Overall, the dominant secondary structural elements remain stable throughout the simulation for both complexes.

https://doi.org/10.1371/journal.pone.0342058.s022

(TIF)

S11 Fig. Molecular dynamics simulation results by GROMACS for ctxB3-A. indica (Mol 1) and ctxB7-A. indica (Mol 1) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-A. indica (Mol 2) complex, and (G) number of hydrogen bonds in ctxB7-A. indica (Mol 1) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents the measured values of different analyses, except for (E), where horizontal axis represents residue index. The green line indicates ctxB3-A. indica (Mol 1) complex, and the blue line indicates ctxB7-A. indica (Mol 1) complex. Ligand movement RMSD for ctxB3-A. indica (Mol 1) complex shifted at the beginning of the simulation, and after which it remained stable. Ligand movement RMSD for ctxB7-A. indica (Mol 1) complex gradually increased, suggesting that the ligand may have steadily shifted from the initial binding pocket.

https://doi.org/10.1371/journal.pone.0342058.s023

(TIF)

S12 Fig. Molecular dynamics simulation results by GROMACS for ctxB3-A. indica (Mol 2) and ctxB7-A. indica (Mol 2) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-A. indica (Mol 2) complex, and (G) number of hydrogen bonds in ctxB7-A. indica (Mol 2) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents the measured values of different analyses, except for (E), where horizontal axis represents residue index. The green line indicates ctxB3-A. indica (Mol 2) complex, and the blue line indicates ctxB7-A. indica (Mol 2) complex. Ligand movement RMSD for both complexes of A. indica (Mol 2) with ctxB3 and ctxB7 faced several drifts until 20 ns, and stabilized thereafter.

https://doi.org/10.1371/journal.pone.0342058.s024

(TIF)

S13 Fig. Molecular dynamics simulation results by GROMACS for ctxB3-M. alba (Mol 10) and ctxB7-M. alba (Mol 10) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-M. alba (Mol 10) complex, and (G) number of hydrogen bonds in ctxB7-M. alba (Mol 10) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents the measured values of different analyses, except for (E), where horizontal axis represents residue index. The green line indicates ctxB3-M. alba (Mol 10) complex, and the blue line indicates ctxB7-M. alba (Mol 10) complex.

https://doi.org/10.1371/journal.pone.0342058.s025

(TIF)

S14 Fig. Molecular dynamics simulation results by GROMACS for ctxB3-A. bidentata (Mol 1) and ctxB7-A. bidentata (Mol 1) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-M. bidentata (Mol 1) complex, and (G) number of hydrogen bonds in ctxB7-M. bidentata (Mol 1) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents measured values of different analyses, except for (E), where the horizontal axis represents residue index. The green line indicates ctxB3-M. bidentata (Mol 1) complex, and the blue line indicates ctxB7-M. bidentata (Mol 1) complex. Ligand movement RMSD for both complexes of M. bidentata (Mol 1) with ctxB3 and ctxB7 faced several drifts until 30 ns, and stabilized thereafter.

https://doi.org/10.1371/journal.pone.0342058.s026

(TIF)

S15 Fig. Molecular dynamics simulation results by GROMACS for ctxB3-B. flabellifer (Mol 2) and ctxB7-B. flabellifer (Mol 2) complexes.

(A) RMSD of protein backbone, (B) ligand movement RMSD, (C) ligand conformation RMSD, (D) radius of gyration, (E) protein residue root mean square fluctuation (RMSF), (F) number of hydrogen bonds in ctxB3-B. flabellifer (Mol 2) complex, and (G) number of hydrogen bonds in ctxB7-B. flabellifer (Mol 2) complex. In each of the plots, horizontal axis represents simulation time (in ns), and vertical axis represents measured values of different analyses, except for (E), where horizontal axis represents residue index. The green line indicates ctxB3-B. flabellifer (Mol 2) complex, and the blue line indicates ctxB7-B. flabellifer (Mol 2) complex. Ligand movement RMSD for both complexes of B. flabellifer (Mol 2) with ctxB3 and ctxB7 faced several drifts until 12 ns, and stabilized thereafter.

https://doi.org/10.1371/journal.pone.0342058.s027

(TIF)

S16 Fig. MM-PBSA binding free energies (kJ/mol) of all 10 ctxB-phytochemical complexes by YASARA and GROMACS.

The left panel contains the results from YASARA software packages, and the right panel contains the results from GROMACS software packages. In each of the plots, the horizontal axis represents simulation time (in ns), and vertical axis represents values of the energy measurements (kJ/mol), green line indicates ctxB3-phytochemical complexes, and the blue line indicates ctxB7-phytochemical complexes. Recoded names of the phytochemicals corresponding to the complexes are textualized within the figures. Higher positive binding energies indicate favorable binding in YASARA, and more negative binding energies indicate favorable binding in GROMACS. Both software packages showed similar trends in binding energy, consistently indicating favorable interactions.

https://doi.org/10.1371/journal.pone.0342058.s028

(TIF)

S17 Fig. Per residue binding free energy decomposition of ctxB-phytochemical complexes.

Panel A shows Azadirachta indica (Mol 2), and Panel B shows Azadirachta indica (Mol 1). In each panel, the horizontal axis represents ctxB variants (ctxB3, ctxB7), and the vertical axis represents the amino acid residues with their positions. Orange color indicates negative (favorable) values, purple indicates positive (unfavorable) values, and white denotes near-zero contributions. A diverse set of top energy contributed amino acids was observed across different ctxB variants.

https://doi.org/10.1371/journal.pone.0342058.s029

(TIF)

S18 Fig. Per residue binding free energy decomposition for all ctxB-phytochemical complexes.

The horizontal axis represents the names of complexes, and the vertical axis represents the amino acid residues with their positions. Orange color indicates negative (favorable) values, purple indicates positive (unfavorable) values, and white denotes near-zero contributions. A total of 70 amino acids out of 124 were assembled in this analysis, collectively accounting for ~80% of the total binding energy of each complex, with individual residues contributing favorably (≤−0.5 kJ/mol) to the total binding energy.

https://doi.org/10.1371/journal.pone.0342058.s030

(TIF)

Acknowledgments

This project was conducted as a non-profit collaborative effort between icddr,b, and the University of Rajshahi. icddr,b extends its gratitude to the Governments of the People’s Republic of Bangladesh and Canada for their unrestricted support. We thank Kazi Ahsan from the School of Medicine at Washington University, St. Louis, USA, for his valuable comments on the draft manuscript, which helped enhance its quality.

References

  1. 1. Kaper JB, Morris JG Jr, Levine MM. Cholera. Clin Microbiol Rev. 1995;8(1):48–86. pmid:7704895
  2. 2. Finkelstein RA. Cholera, Vibrio cholerae O1 and O139, and Other Pathogenic Vibrios. 4th edition. Baron S, editor. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Available: https://www.ncbi.nlm.nih.gov/books/NBK8407/
  3. 3. Taylor DL, Kahawita TM, Cairncross S, Ensink JHJ. The Impact of Water, Sanitation and Hygiene Interventions to Control Cholera: A Systematic Review. PLoS One. 2015;10(8):e0135676. pmid:26284367
  4. 4. World Health Organization (WHO). Cholera upsurge. 30 Apr 2024 [cited 29 Apr 2025]. Available: https://www.who.int/emergencies/situations/cholera-upsurge
  5. 5. Millions at risk from cholera due to lack of clean water, soap and toilets, and shortage of cholera vaccine. WHO. 20 Mar 2024. Accessed 18 Feb 2025. Available: https://www.who.int/news/item/20-03-2024-millions-at-risk-from-cholera-due-to-lack-of-clean-water-soap-and-toilets-and-shortage-of-cholera-vaccine#:~:text=*%20News/%20*%20Millions%20at%20risk%20from,and%20toilets%2C%20and%20shortage%20of%20cholera%20vaccine
  6. 6. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832. pmid:26043000
  7. 7. Albert MJ. Vibrio cholerae O139 Bengal. J Clin Microbiol. 1994;32(10):2345–9. pmid:7814463
  8. 8. Beyhan S, Tischler AD, Camilli A, Yildiz FH. Differences in gene expression between the classical and El Tor biotypes of Vibrio cholerae O1. Infect Immun. 2006;74(6):3633–42. pmid:16714595
  9. 9. Conner JG, Teschler JK, Jones CJ, Yildiz FH. Staying Alive: Vibrio cholerae’s Cycle of Environmental Survival, Transmission, and Dissemination. Microbiol Spectr. 2016;4(2):10.1128/microbiolspec.VMBF-0015–2015. pmid:27227302
  10. 10. Thiagarajah JR, Donowitz M, Verkman AS. Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol. 2015;12(8):446–57. pmid:26122478
  11. 11. Munos MK, Walker CLF, Black RE. The effect of oral rehydration solution and recommended home fluids on diarrhoea mortality. Int J Epidemiol. 2010;39 Suppl 1(Suppl 1):i75-87. pmid:20348131
  12. 12. Ghosh A, Ramamurthy T. Antimicrobials & cholera: are we stranded?. Indian J Med Res. 2011;133(2):225–31. pmid:21415499
  13. 13. Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med. 2006;354(23):2452–62. pmid:16760445
  14. 14. Narendrakumar L, Gupta SS, Johnson JB, Ramamurthy T, Thomas S. Molecular Adaptations and Antibiotic Resistance in Vibrio cholerae: A Communal Challenge. Microb Drug Resist. 2019;25(7):1012–22. pmid:31021308
  15. 15. Jubyda FT, Nahar KS, Barman I, Johura F-T, Islam MT, Sultana M, et al. Vibrio cholerae O1 associated with recent endemic cholera shows temporal changes in serotype, genotype, and drug-resistance patterns in Bangladesh. Gut Pathog. 2023;15(1):17. pmid:37046358
  16. 16. Monir MM, Islam MT, Mazumder R, Mondal D, Nahar KS, Sultana M, et al. Genomic attributes of Vibrio cholerae O1 responsible for 2022 massive cholera outbreak in Bangladesh. Nat Commun. 2023;14(1):1154. pmid:36859426
  17. 17. Das B, Verma J, Kumar P, Ghosh A, Ramamurthy T. Antibiotic resistance in Vibrio cholerae: Understanding the ecology of resistance genes and mechanisms. Vaccine. 2020;38 Suppl 1:A83–92. pmid:31272870
  18. 18. Gupta R, Sharma S. Role of alternatives to antibiotics in mitigating the antimicrobial resistance crisis. Indian J Med Res. 2022;156(3):464–77. pmid:36751744
  19. 19. Mao N, Cubillos-Ruiz A, Cameron DE, Collins JJ. Probiotic strains detect and suppress cholera in mice. Sci Transl Med. 2018;10(445):eaao2586. pmid:29899022
  20. 20. Falklind-Jerkérus S, Felici F, Cavalieri C, Lo Passo C, Garufi G, Pernice I, et al. Peptides mimicking Vibrio cholerae O139 capsular polysaccharide elicit protective antibody response. Microbes Infect. 2005;7(15):1453–60. pmid:16046165
  21. 21. Yen M, Cairns LS, Camilli A. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat Commun. 2017;8:14187. pmid:28146150
  22. 22. Yamasaki S, Asakura M, Neogi SB, Hinenoya A, Iwaoka E, Aoki S. Inhibition of virulence potential of Vibrio cholerae by natural compounds. Indian J Med Res. 2011;133(2):232–9. pmid:21415500
  23. 23. Haelle T. The Staggering Success of Vaccines. Nature. 2024;634(8035):S34–9. pmid:39443787
  24. 24. Bi Q, Ferreras E, Pezzoli L, Legros D, Ivers LC, Date K, et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(10):1080–8. pmid:28729167
  25. 25. Raheem SG, Salh KK, Ibrahim KS, Gorji AE. In-Silico Designing a Multi-Peptide Vaccine: Against Vibrio Cholera. Int J Pept Res Ther. 2021;27(2):1541–53.
  26. 26. Desai SN, Pezzoli L, Alberti KP, Martin S, Costa A, Perea W, et al. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era. Hum Vaccin Immunother. 2017;13(3):579–87. pmid:27813703
  27. 27. Rebecca L. Root. Countries grapple with global shortage of oral cholera vaccine. devex. 23 Dec 2024. Accessed 18 Feb 2025. Available: https://www.devex.com/news/countries-grapple-with-global-shortage-of-oral-cholera-vaccine-108935#:~:text=Amid%20climate%20change%20and%20conflict,equipped%20to%20meet%20the%20need.&text=In%20February%2C%20the%20World%20Health,Bangladesh%2C%20or%20icddr%2Cb
  28. 28. Ali M, Qadri F, Kim DR, Islam MT, Im J, Ahmmed F, et al. Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial. Lancet Infect Dis. 2021;21(10):1407–14. pmid:34146473
  29. 29. Khare T, Anand U, Dey A, Assaraf YG, Chen Z-S, Liu Z, et al. Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens. Front Pharmacol. 2021;12:720726. pmid:34366872
  30. 30. AlSheikh HMA, Sultan I, Kumar V, Rather IA, Al-Sheikh H, Tasleem Jan A, et al. Plant-Based Phytochemicals as Possible Alternative to Antibiotics in Combating Bacterial Drug Resistance. Antibiotics (Basel). 2020;9(8):480. pmid:32759771
  31. 31. Fazil MHUT, Konda Reddy K, Pandey HP, Kumar S. Molecular Modeling and Drug Design: A Contemporary Analysis in Vibrio cholerae. Current trends in Bioinformatics: An Insight. Singapore: Springer Singapore; 2018. pp. 107–119. https://doi.org/10.1007/978-981-10-7483-7_6
  32. 32. Singh UB, Singh S, Malviya D, Karthikeyan N, Imran Mohd, Chaurasia R, et al. Integration of anti-penetrant tricyclazole, signaling molecule salicylic acid and root associated Pseudomonas fluorescens enhances suppression of Bipolaris sorokiniana in bread wheat (Triticum aestivum L.). J Plant Pathol. 2019;101(4):943–54.
  33. 33. Vivek-Ananth RP, Mohanraj K, Sahoo AK, Samal A. IMPPAT 2.0: An Enhanced and Expanded Phytochemical Atlas of Indian Medicinal Plants. ACS Omega. 2023;8(9):8827–45. pmid:36910986
  34. 34. Sánchez J, Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci. 2008;65(9):1347–60. pmid:18278577
  35. 35. Minke WE, Roach C, Hol WG, Verlinde CL. Structure-based exploration of the ganglioside GM1 binding sites of Escherichia coli heat-labile enterotoxin and cholera toxin for the discovery of receptor antagonists. Biochemistry. 1999;38(18):5684–92. pmid:10231518
  36. 36. Basu I, Mukhopadhyay C. Insights into binding of cholera toxin to GM1 containing membrane. Langmuir. 2014;30(50):15244–52. pmid:25425333
  37. 37. Fan E, Merritt EA, Zhang Z, Pickens JC, Roach C, Ahn M, et al. Exploration of the GM1 receptor-binding site of heat-labile enterotoxin and cholera toxin by phenyl-ring-containing galactose derivatives. Acta Crystallogr D Biol Crystallogr. 2001;57(Pt 2):201–12. pmid:11173465
  38. 38. Wands AM, Fujita A, McCombs JE, Cervin J, Dedic B, Rodriguez AC, et al. Fucosylation and protein glycosylation create functional receptors for cholera toxin. Elife. 2015;4:e09545. pmid:26512888
  39. 39. Cervin J, Wands AM, Casselbrant A, Wu H, Krishnamurthy S, Cvjetkovic A, et al. GM1 ganglioside-independent intoxication by Cholera toxin. PLoS Pathog. 2018;14(2):e1006862. pmid:29432456
  40. 40. Heggelund JE, Haugen E, Lygren B, Mackenzie A, Holmner Å, Vasile F, et al. Both El Tor and classical cholera toxin bind blood group determinants. Biochem Biophys Res Commun. 2012;418(4):731–5. pmid:22305717
  41. 41. Mandal PK, Branson TR, Hayes ED, Ross JF, Gavín JA, Daranas AH, et al. Towards a structural basis for the relationship between blood group and the severity of El Tor cholera. Angew Chem Int Ed Engl. 2012;51(21):5143–6. pmid:22488789
  42. 42. Angström J, Bäckström M, Berntsson A, Karlsson N, Holmgren J, Karlsson KA, et al. Novel carbohydrate binding site recognizing blood group A and B determinants in a hybrid of cholera toxin and Escherichia coli heat-labile enterotoxin B-subunits. J Biol Chem. 2000;275(5):3231–8. pmid:10652309
  43. 43. Pandey MM, Rastogi S, Rawat AKS. Indian traditional ayurvedic system of medicine and nutritional supplementation. Evid Based Complement Alternat Med. 2013;2013:376327. pmid:23864888
  44. 44. Dash VB, Kashyap VL. Ayurveda Materia Medica. New Delhi: Concept publishing Company; Available: http://www.new.dli.ernet.in/handle/2015/490299
  45. 45. Pal BB, Behera DR, Nayak SR, Nayak AK. Origin and Dissemination of Altered El Tor Vibrio cholerae O1 Causing Cholera in Odisha, India: Two and Half Decade’s View. Front Microbiol. 2021;12:757986. pmid:34867883
  46. 46. Monir MM, Hossain T, Morita M, Ohnishi M, Johura F-T, Sultana M, et al. Genomic Characteristics of Recently Recognized Vibrio cholerae El Tor Lineages Associated with Cholera in Bangladesh, 1991 to 2017. Microbiol Spectr. 2022;10(2):e0039122. pmid:35315699
  47. 47. Kim EJ, Lee CH, Nair GB, Kim DW. Whole-genome sequence comparisons reveal the evolution of Vibrio cholerae O1. Trends Microbiol. 2015;23(8):479–89. pmid:25913612
  48. 48. Pal BB, Khuntia HK, Samal SK, Kar SK, Patnaik B. Epidemics of severe cholera caused by El Tor Vibrio cholerae O1 Ogawa possessing the ctxB gene of the classical biotype in Orissa, India. Int J Infect Dis. 2010;14(5):e384-9. pmid:19781971
  49. 49. Kumar P, Jain M, Goel AK, Bhadauria S, Sharma SK, Kamboj DV, et al. A large cholera outbreak due to a new cholera toxin variant of the Vibrio cholerae O1 El Tor biotype in Orissa, Eastern India. J Med Microbiol. 2009;58(Pt 2):234–8. pmid:19141742
  50. 50. Lassalle F, Al-Shalali S, Al-Hakimi M, Njamkepo E, Bashir IM, Dorman MJ, et al. Genomic epidemiology reveals multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen. Nat Microbiol. 2023;8(10):1787–98. pmid:37770747
  51. 51. Chabuka L, Choga WT, Mavian CN, Moir M, Morgenstern C, Tegaly H, et al. Genomic Surveillance of Climate-Amplified Cholera Outbreak, Malawi, 2022-2023. Emerg Infect Dis. 2025;31(6):1090–9. pmid:40439430
  52. 52. Smith AM, Sekwadi P, Erasmus LK, Lee CC, Stroika SG, Ndzabandzaba S, et al. Imported Cholera Cases, South Africa, 2023. Emerg Infect Dis. 2023;29(8):1687–90. pmid:37352549
  53. 53. Abou Fayad A, Rafei R, Njamkepo E, Ezzeddine J, Hussein H, Sinno S, et al. An unusual two-strain cholera outbreak in Lebanon, 2022-2023: a genomic epidemiology study. Nat Commun. 2024;15(1):6963. pmid:39138238
  54. 54. Benamrouche N, Belkader C, Njamkepo E, Zemam SS, Sadat S, Saighi K, et al. Outbreak of Imported Seventh Pandemic Vibrio cholerae O1 El Tor, Algeria, 2018. Emerg Infect Dis. 2022;28(6):1241–5. pmid:35608654
  55. 55. Maciel-Guerra A, Babaarslan K, Baker M, Rahman A, Hossain M, Sadique A, et al. Core and accessory genomic traits of Vibrio cholerae O1 drive lineage transmission and disease severity. Nat Commun. 2024;15(1):8231. pmid:39313510
  56. 56. Chaguza C, Chibwe I, Chaima D, Musicha P, Ndeketa L, Kasambara W, et al. Genomic insights into the 2022-2023Vibrio cholerae outbreak in Malawi. Nat Commun. 2024;15(1):6291. pmid:39060226
  57. 57. Taylor-Brown A, Afrad MH, Khan AI, Lassalle F, Islam MT, Tanvir NA, et al. Genomic epidemiology of Vibrio cholerae during a mass vaccination campaign of displaced communities in Bangladesh. Nat Commun. 2023;14(1):3773. pmid:37355673
  58. 58. Pal BB, Khuntia HK, Nayak SR, Mohanty A, Biswal B. Vibrio cholerae O1 Ogawa Strains Carrying the ctxB7 Allele Caused a Large Cholera Outbreak during 2014 in the Tribal Areas of Odisha, India. Jpn J Infect Dis. 2017;70(5):549–53. pmid:28674316
  59. 59. Breurec S, Franck T, Njamkepo E, Mbecko J-R, Rauzier J, Sanke-Waïgana H, et al. Seventh Pandemic Vibrio cholerae O1 Sublineages, Central African Republic. Emerg Infect Dis. 2021;27(1):262–6. pmid:33350910
  60. 60. Hossain ZZ, Leekitcharoenphon P, Dalsgaard A, Sultana R, Begum A, Jensen PKM, et al. Comparative genomics of Vibrio cholerae O1 isolated from cholera patients in Bangladesh. Lett Appl Microbiol. 2018;67(4):329–36. pmid:29981154
  61. 61. Morita D, Morita M, Alam M, Mukhopadhyay AK, Johura F-T, Sultana M, et al. Whole-Genome Analysis of Clinical Vibrio cholerae O1 in Kolkata, India, and Dhaka, Bangladesh, Reveals Two Lineages of Circulating Strains, Indicating Variation in Genomic Attributes. mBio. 2020;11(6):e01227-20. pmid:33172996
  62. 62. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Res. 2023;51(D1):D1373–80. pmid:36305812
  63. 63. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296–303. pmid:29788355
  64. 64. Ramachandran GN, Ramakrishnan C, Sasisekharan V. Stereochemistry of polypeptide chain configurations. J Mol Biol. 1963;7:95–9. pmid:13990617
  65. 65. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, et al. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 2007;35(Web Server issue):W522-5. pmid:17488841
  66. 66. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33(Web Server issue):W368-71. pmid:15980491
  67. 67. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91. pmid:19399780
  68. 68. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011;3:33. pmid:21982300
  69. 69. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021;61(8):3891–8. pmid:34278794
  70. 70. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61. pmid:19499576
  71. 71. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. pmid:28256516
  72. 72. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015;58(9):4066–72. pmid:25860834
  73. 73. Gu Y, Yu Z, Wang Y, Chen L, Lou C, Yang C, et al. admetSAR3.0: a comprehensive platform for exploration, prediction and optimization of chemical ADMET properties. Nucleic Acids Res. 2024;52(W1):W432–8. pmid:38647076
  74. 74. Fu L, Shi S, Yi J, Wang N, He Y, Wu Z, et al. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Res. 2024;52: W422–W431.
  75. 75. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337–41. pmid:24981612
  76. 76. Di L. The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol. 2014;10(3):379–93. pmid:24392841
  77. 77. van Waterschoot RAB, Schinkel AH. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev. 2011;63(2):390–410. pmid:21490128
  78. 78. BIOVIA, Dassault Systèmes, Discovery Studio Visualizer. San Diego: Dassault Systèmes. 2020.
  79. 79. Krieger E, Vriend G, Spronk C. YASARA - Yet Another Scientific Artificial Reality Application. http://www.yasara.org/
  80. 80. Dickson CJ, Madej BD, Skjevik AA, Betz RM, Teigen K, Gould IR, et al. Lipid14: The Amber Lipid Force Field. J Chem Theory Comput. 2014;10(2):865–79. pmid:24803855
  81. 81. Boonstra S, Onck PR, Giessen E van der. CHARMM TIP3P Water Model Suppresses Peptide Folding by Solvating the Unfolded State. J Phys Chem B. 2016;120(15):3692–8. pmid:27031562
  82. 82. Krieger E, Vriend G. New ways to boost molecular dynamics simulations. J Comput Chem. 2015;36(13):996–1007. pmid:25824339
  83. 83. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. The Journal of Chemical Physics. 1995;103(19):8577–93.
  84. 84. Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins. 2004;57(4):678–83. pmid:15390263
  85. 85. Krieger E, Koraimann G, Vriend G. Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field. Proteins. 2002;47(3):393–402. pmid:11948792
  86. 86. Weis A, Katebzadeh K, Söderhjelm P, Nilsson I, Ryde U. Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. J Med Chem. 2006;49(22):6596–606. pmid:17064078
  87. 87. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25.
  88. 88. Kumari R, Kumar R, Open Source Drug Discovery Consortium, Lynn A. g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model. 2014;54(7):1951–62. pmid:24850022
  89. 89. Zhang Y, Skolnick J. TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res. 2005;33(7):2302–9. pmid:15849316
  90. 90. Hsin K-Y, Ghosh S, Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS One. 2013;8(12):e83922. pmid:24391846
  91. 91. Cholera Toxin (CT): Secretion by the Vibrios. Cholera Toxins. Springer Berlin Heidelberg. p. 165–84. https://doi.org/10.1007/978-3-540-88452-1_10
  92. 92. Merritt EA, Sarfaty S, van den Akker F, L’Hoir C, Martial JA, Hol WG. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci. 1994;3(2):166–75. pmid:8003954
  93. 93. De Wolf MJ, Van Dessel GA, Lagrou AR, Hilderson HJ, Dierick WS. pH-induced transitions in cholera toxin conformation: a fluorescence study. Biochemistry. 1987;26(13):3799–806. pmid:3651415
  94. 94. Ruddock LW, Coen JJ, Cheesman C, Freedman RB, Hirst TR. Assembly of the B subunit pentamer of Escherichia coli heat-labile enterotoxin. Kinetics and molecular basis of rate-limiting steps in vitro. J Biol Chem. 1996;271(32):19118–23. pmid:8702586
  95. 95. Heim JB, Hodnik V, Heggelund JE, Anderluh G, Krengel U. Crystal structures of cholera toxin in complex with fucosylated receptors point to importance of secondary binding site. Sci Rep. 2019;9(1):12243. pmid:31439922
  96. 96. Antimicrobial resistance: a silent pandemic. Nat Commun. 2024;15(1):6198. pmid:39043632
  97. 97. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55. pmid:35065702
  98. 98. Newman DJ. Natural products as leads to potential drugs: an old process or the new hope for drug discovery?. J Med Chem. 2008;51(9):2589–99. pmid:18393402
  99. 99. Pant A, Das B, Bhadra RK. CTX phage of Vibrio cholerae: Genomics and applications. Vaccine. 2020;38 Suppl 1:A7–12. pmid:31272871
  100. 100. Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science. 1996;272(5270):1910–4. pmid:8658163
  101. 101. Sinclair HR, Smejkal CW, Glister C, Kemp F, van den Heuvel E, de Slegte J, et al. Sialyloligosaccharides inhibit cholera toxin binding to the GM1 receptor. Carbohydr Res. 2008;343(15):2589–94. pmid:18703180
  102. 102. Heggelund JE, Mackenzie A, Martinsen T, Heim JB, Cheshev P, Bernardi A, et al. Towards new cholera prophylactics and treatment: Crystal structures of bacterial enterotoxins in complex with GM1 mimics. Sci Rep. 2017;7(1):2326. pmid:28539625
  103. 103. Sarwar S, Ali A, Pal M, Chakrabarti P. Zinc oxide nanoparticles provide anti-cholera activity by disrupting the interaction of cholera toxin with the human GM1 receptor. J Biol Chem. 2017;292(44):18303–11. pmid:28882894
  104. 104. Cherubin P, Garcia MC, Curtis D, Britt CBT, Craft JW Jr, Burress H, et al. Inhibition of Cholera Toxin and Other AB Toxins by Polyphenolic Compounds. PLoS One. 2016;11(11):e0166477. pmid:27829022
  105. 105. Chatterjee S, Asakura M, Chowdhury N, Neogi SB, Sugimoto N, Haldar S, et al. Capsaicin, a potential inhibitor of cholera toxin production in Vibrio cholerae. FEMS Microbiol Lett. 2010;306(1):54–60. pmid:20337712
  106. 106. Branderhorst HM, Liskamp RMJ, Visser GM, Pieters RJ. Strong inhibition of cholera toxin binding by galactose dendrimers. Chem Commun (Camb). 2007;(47):5043–5. pmid:18049747
  107. 107. Liu J, Begley D, Mitchell DD, Verlinde CLMJ, Varani G, Fan E. Multivalent drug design and inhibition of cholera toxin by specific and transient protein-ligand interactions. Chem Biol Drug Des. 2008;71(5):408–19. pmid:18373548
  108. 108. Fazil MHUT, Kumar S, Farmer R, Pandey HP, Singh DV. Binding efficiencies of carbohydrate ligands with different genotypes of cholera toxin B: molecular modeling, dynamics and docking simulation studies. J Mol Model. 2012;18(1):1–10. pmid:21409571
  109. 109. Friedman M, Henika PR, Mackey BE. Effect of feeding solanidine, solasodine and tomatidine to non-pregnant and pregnant mice. Food Chem Toxicol. 2003;41(1):61–71. pmid:12453729
  110. 110. Karaca M, Erbaş O. E N T A L and B A S I C solanine poisoning: Effects, risks, and management strategies. Journal of Experimental and Basic Medical Sciences. 2024;5:189–93.
  111. 111. Kwofie SK, Annan DG, Adinortey CA, Boison D, Kwarko GB, Abban RA, et al. Identification of novel potential inhibitors of varicella-zoster virus thymidine kinase from ethnopharmacologic relevant plants through an in-silico approach. J Biomol Struct Dyn. 2022;40(23):12932–47. pmid:34533095
  112. 112. Semwal P, Painuli S, Abu-Izneid T, Rauf A, Sharma A, Daştan SD, et al. Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives. Oxid Med Cell Longev. 2022;2022:1035441. pmid:35677108
  113. 113. Moriwaki S, Murakami H, Takahashi N, Uemura T, Taketani K, Hoshino S, et al. Yamogenin in fenugreek inhibits lipid accumulation through the suppression of gene expression in fatty acid synthesis in hepatocytes. Biosci Biotechnol Biochem. 2014;78(7):1231–6. pmid:25229863